A Study Of The Safety, Tolerability And Effective Of Voriconazole For The Treatment Of Serious Candida Infection And Candida Infection Of The Throat In Pediatric Patients

Inclusion Criteria: * Male or female 2 to \<18 years of age; Subjects 2 to \<12 years of age will be permitted to enroll in this study only after a Pfizer sponsored pharmacokinetic study confirms the proposed dosage corresponding to this age group is appropriate. * Patients with confirmed Candida infection of the blood, body tissues, or the esophagus. * Patient's doctor feels voriconazole is an appropriate choice of therapy. Exclusion Criteria: * A known allergy to voriconazole or to azole to antifungal drugs. * Females who are pregnant, lactating (breast feeding) or planning a pregnancy during the course of the study, or who are of childbearing potential and not using highly effective method of birth control. * A patient who is receiving treatment with a drug know to interfere with the heart's electrical system (QTc prolongation). * A patient who is receiving treatment with a drug that is not permitted to be used with voriconazole. * For primary therapy: a patient who has received more than 48 hours of antifungal therapy for the current episode of Candida infection. * A patient with significant underlying liver disease at the time of enrollment in the study. * A patient with significant renal disease (CrCl \< 50 ml/min) at the time of enrollment in the study. * A patient with a high likelihood of death within 72 hours of study enrollment due to factors unrelated to Candida infection.